InsiderTrades

Form 4 for OTLK Outlook Therapeutics, Inc.

Accepted 2026-08-14 20:57:45 ET · period of report 2026-08-14 · accession 0001104659-26-097406 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-08-14 20:57 2026-08-14 OTLK Jahr Robert Charles CEO, Dir P - Purchase — +151.5K 151.5K New —
D 2026-08-14 20:57 2026-08-14 OTLK Jahr Robert Charles CEO, Dir P - Purchase — +151.5K 151.5K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-14 P A 151,515 — 151,515 D — — (F1) On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
2 Derivative Warrants (right to buy) 2026-08-14 P A 151,515 — 151,515 D $1.10 · 2026-08-14 to 2031-08-14 151,515 Common Stock (F2) The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. (F1) On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.